WO1995019714A1 - Process for fractionating whey proteins and the components so obtained - Google Patents

Process for fractionating whey proteins and the components so obtained Download PDF

Info

Publication number
WO1995019714A1
WO1995019714A1 PCT/FI1995/000027 FI9500027W WO9519714A1 WO 1995019714 A1 WO1995019714 A1 WO 1995019714A1 FI 9500027 W FI9500027 W FI 9500027W WO 9519714 A1 WO9519714 A1 WO 9519714A1
Authority
WO
WIPO (PCT)
Prior art keywords
whey
column
component
stage
solution
Prior art date
Application number
PCT/FI1995/000027
Other languages
French (fr)
Inventor
Marko Outinen
Matti Harju
Olli Tossavainen
Pirkko Antila
Original Assignee
Valio Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valio Oy filed Critical Valio Oy
Priority to EP95905668A priority Critical patent/EP0757522A1/en
Priority to AU14193/95A priority patent/AU1419395A/en
Publication of WO1995019714A1 publication Critical patent/WO1995019714A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/14Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/146Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
    • A23C9/1465Chromatographic separation of protein or lactose fraction; Adsorption of protein or lactose fraction followed by elution
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine

Definitions

  • the invention relates to a process for fractionating whey proteins. More specifically, the invention relates to a process for fractionating whey or whey protein solution chromatographically select ⁇ ively into an alpha-lactalbumin component and a beta- lactoglobulin component, and to an alpha-lactalbumin component and beta-lactoglobulin component so obtained.
  • the obtained alpha-lactalbumin component is as such suitable for use in infant food formulas
  • the obtained beta-lactoglobulin component in turn is as such suitable for use as a protein component in clinical nutritive preparations and various products of the food industry.
  • Milk whey proteins are used inter alia in infant food formulas on account of their high digestibility and excellent nutritional value.
  • the pro ⁇ tein of infant food formulas is composed of milk casein and whey protein in a ratio of 40:60 (casein: whey protein) , which corresponds to the ratio between casein and whey protein in human milk.
  • the protein composition of infant food formulas does not fully correspond to that of human milk, as the whey protein of cow's milk differs in composition from the whey protein of human milk; human milk contains no beta-lactoglobulin ( ⁇ -LG), which is the main component of the whey protein of cow's milk.
  • ⁇ -LG beta-lactoglobulin
  • the whey protein of cow's milk alpha-lactalbumin ( ⁇ - LA)
  • ⁇ - LA alpha-lactalbumin
  • the protein of human milk is mainly composed of - LA (approx. 40% by weight)
  • ⁇ -LG As certain functional properties of ⁇ -LG (such as solubility within a wide pH range and good gelific- ation ability) are clearly better than those of whey protein concentrate (WPC), ⁇ -LG is regarded as well suited for use in the food industry. At present, the food industry uses WPC but is waiting for the entry into market of an economically feasible beta-lacto ⁇ globulin [D.M. Mulvihill, Food Research Quarterly 51 (1991) 65-73]. WPC is used e.g. in clinical nutritive preparations. In yoghurts, fresh cheeses and curd, it is used to replace casein. In curd, as much as 20% by weight of the casein can be replaced with whey pro ⁇ tein.
  • WPC fatless WPC
  • flavoured milk drinks such as cocoa
  • WPC has also been used in the production of ice-cream, ice-lollies, meringue (only fatless WPC) and chocolate coatings [D. M. Mulvihill, Food Research Quarterly 51 (1991), 65-73].
  • Spherosil QMA resin is composed of silica particles (diameter between 100 and 300 ⁇ m) coated with styrene vinyl triethoxysilane co- polymer to which quaternary ammonium groups are attached. This resin has a mean pore size of 1,250 A, a pore volume of 1 cm 3 /g and a specific surface area of 25 m 2 /g.
  • Example 8 the Thibault process allows native whey (ash content less than 1% by weight) to be treated only within a pH range be ⁇ tween 4 and 6. Whey with a high salt content (ash content between 1 and 3% by weight) can be treated within a pH range between 6 and 8.
  • the object of this invention is to provide an industrially applicable process which avoids the above-mentioned drawbacks and which allows whey or whey protein solution to be fractionated selectively into an alpha-lactalbumin component and a beta-lacto ⁇ globulin component.
  • the invention relates to a process for frac ⁇ tionating whey or whey protein solution chromato- graphically selectively into an alpha-lactalbumin component and a beta-lactoglobulin component.
  • the process is characterized by a) clarifying a batch of whey or whey protein solution and, if required, removing glycomacropeptides from it; b) passing whey or whey protein solution treated at stage a) through a chromatography column packed with a strong polystyrene-based anion exchange resin, which resin has a great pore size ranging between 1,000 and 2,000 A and a pore volume of at least 0.9 cm 3 /g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to a styrene-divinyl-benzene- polymer matrix, and which has a particle diameter between 300 and 600 ⁇ m, and recovering the fraction leaving the
  • the process according to the invention is suitable for fractionating proteins from different types of wheys and whey protein solutions, such as cheese and casein whey, demineralized whey and whey protein concentrate. It is particularly well suited for fractionating casein whey into an alpha-lact- albumin component and a beta-lactoglobulin component.
  • whey or whey protein solution can be fractionated more effect ⁇ ively than previously by the strong anion exchange resins Diaion HPA 25 and HPA 75 (Resindion, Mitsubishi Kasei Corp., Japan), which are much cheaper than the Spherosil QMA resins.
  • Quaternary alkyl amine (HPA 25) or alkyl alkanoamine (HPA 75) groups are attached to the styrene-divinyl-benzene-poly er matrix of these HPA resins. Due to their great pore size (1,000 to 2,000 A), pore volume (0.9 cm 3 /g) and specific surface area (23 to 25 m 2 /g), these HPA resins are suitable for separating large molecules.
  • HPA resins The price of the HPA resins is only about 1/100 of that of the Spherosil QMA resins.
  • HPA resins are well suited for industrial applications on account of their appropriate particle size (diameter 300 too 600 ⁇ m) and mechanical strength.
  • a further advantage of the HPA resins is that protein attached to them can be eluted by a 2 to 5 wt.% NaCl solution, whereas less safe hydrochloric acid has to be used to elute protein attached to Spherosil QMA resin in the process described by P.J. Skudder in J. Dairy Res . , 52 (1985), 167-181.
  • the NaCl treatment is also to be preferred over HC1 from the viewpoint of preserving the nativity of the protein.
  • the process according to the invention allows most of ⁇ -LG to be separated from native whey (ash content less than 1% by weight) into a fraction substantially free of other whey proteins within a pH range between 6 and 7 without pH adjustment, whereas native whey can be treated in the process described in US Patent 5,077,067 only within a pH range between 4 and 6.
  • the attached drawings give chromatograms obtained by Fast Protein Liquid Chromatography, FPLC, for the alpha-lactalbumin and beta-lactoglobulin fractions of whey.
  • Figure 1 shows FPLC chromatograms obtained for the alpha-lactalbumin and beta-lactoglobulin fractions of casein whey with HPA 75 resin according to the in ⁇ vention;
  • Figure 2 shows FPLC chromatograms obtained for the alpha-lactalbumin and beta-lactoglobulin fractions of casein whey with Spherosil QMA LS resin.
  • whey or whey protein solu ⁇ tion is clarified by precipitating residual casein, phospholipoprotein and calcium phosphate by an in ⁇ crease in pH, an addition of CaCl 2 '2H 2 0 and a light heat treatment, and by removing the precipitate by decantation, centrifugation or microfiltration.
  • the clarification method does not significantly affect the protein composition of wheys.
  • whey or whey protein solu ⁇ tion treated at process stage a) is passed through a chromatography column packed with a strong poly ⁇ styrene-based anion exchange resin, which resin has a great pore size between 1,000 and 2,000 A and a pore volume of at least 0.9 cm 3 /g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to the styrene- divinyl-benzene-polymer matrix, and which has a par ⁇ ticle diameter between 300 and 600 ⁇ m, and the fraction leaving the column is recovered.
  • a strong poly ⁇ styrene-based anion exchange resin which resin has a great pore size between 1,000 and 2,000 A and a pore volume of at least 0.9 cm 3 /g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to the s
  • whey or whey protein solution in a corresponding amount with respect to the protein, treated at process stage a), is passed at process stage b) at a pH ranging between 6.0 and 7.0 at a flow rate of 3 to 5 column volumes per hour through a chromatography column packed with a strong polystyrene-based anion exchange resin so that 6 to 7 cm 3 of whey or whey protein solution in a corresponding amount with respect to the protein are passed through the column per 1 cm 3 of resin.
  • the anion exchange resin column treated at stage b) is washed with deionized water, the wash water is combined with the fraction recovered at process stage b) and the obtained solu- tion is recovered as an alpha-lactalbumin component.
  • the recovered alpha-lactalbumin component can be used as such as an ⁇ -LA component particularly in infant food formulas or it can be concentrated and, if desired, dried in a manner known per se before use as an ⁇ -LA component.
  • ⁇ -LG bound to the resin column can be released from the washed anion exchange resin column by eluting with a weak aqueous NaCl solu ⁇ tion, preferably an aqueous 2 to 5 wt.% NaCl solution, and the eluate is recovered as a beta-lactoglobulin component. After having been rinsed with water, the resin is ready for re-use.
  • a weak aqueous NaCl solu ⁇ tion preferably an aqueous 2 to 5 wt.% NaCl solution
  • the recovered beta-lactoglobulin component can be used as such as a ⁇ -LG component e.g. in clinical nutritive preparations or various products of the food industry. It can also be concentrated and, if desired, dried in a manner known per se before use as a ⁇ -LG component.
  • Cheese whey usually contains glycomacropeptide (GMP) formed from milk casein in the production of cheese as a result of the action of a rennet enzyme.
  • GMP glycomacropeptide
  • GMP deteriorates protein fraction- ation with ion exchange resins [P.J. Skudder, J. Dairy Res . , 52 (1985) 167 - 181] and that it may even cause blocking of Spherosil QMA resin.
  • GB Patent Appli ⁇ cation 2,188,526, J. Burton and P.J. Skudder describe a process utilizing Spherosil QMA for removing GMP.
  • GMP can be removed from whey or whey protein solution qualit ⁇ atively, as it can be made to attach to the strong anion exchange resin Diaion HPA 25 or HPA 75 at pH 5.0.
  • Glycomacropeptides possibly present in whey or whey protein solution at stage a) of the process according to the invention are thus removed by passing clarified whey or whey protein solution at pH 5.0 at a flow rate of 3 to 7 column volumes per hour through a chromatography column packed with strong polystyrene- based anion exchange resin, which resin has a great pore size between 1,000 and 2,000 A and a pore volume of at least 0.9 cm 3 /g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to the styrene- divinyl-benzene-polymer matrix, and which has a par ⁇ ticle diameter between 300 and 600 ⁇ m, so that 7 to 10 cm 3 of whey or whey protein solution in a correspond ⁇ ing amount with respect to the protein are passed through the column per 1 cm 3 of resin, and the fraction leaving the column is passed to stage b).
  • Fractionation of whey proteins from cheese whey or cheese whey protein solution purified from GMP is significantly more efficient than from unpurified cheese whey or cheese whey protein solution, and no problems are caused by blocked columns.
  • GMP can be removed considerably more economically than in the above-mentioned known process, as the expensive Spherosil QMA resin can now be replaced with the Diaion HPA 25 or HPA 75 resins, which are markedly cheaper.
  • HC1 can be replaced with a NaCl solution in eluting Diaion HPA 25 or HPA 75 resins.
  • the invention also relates to an alpha-lact ⁇ albumin component which is useful as an ⁇ -LA component particularly in infant food formulas and which is produced by the process according to the invention.
  • the invention relates to a beta- lactoglobulin component which is useful as a ⁇ -LG protein component in the food industry in the produc ⁇ tion of e.g. clinical nutritive preparations and dif ⁇ ferent kinds of food products, such as various drinks, sausages and ice-creams, and which is produced by the process according to the invention.
  • a beta- lactoglobulin component which is useful as a ⁇ -LG protein component in the food industry in the produc ⁇ tion of e.g. clinical nutritive preparations and dif ⁇ ferent kinds of food products, such as various drinks, sausages and ice-creams, and which is produced by the process according to the invention.
  • Example 1
  • casein whey (2,000 cm 3 ) was adjusted between 7.5 and 8.5, and the whey was warmed for 30 min at 50°C, after which it was allowed to stand for 16 h at 5°C. Clear whey was separated from the pre ⁇ cipitated calcium phosphate, fat and lipoproteins through decantation. Clarified whey was additionally filtered through Whatman GF/A filter paper and stored at 5°C. 30 cm 3 of regenerated, strong anion exchange resin Diaion HPA 25 were packed into a chromatography column. 200 cm 3 of casein whey clarified as described above were passed through the resin column at a rate of 100 cm 3 /h at pH 6.5.
  • Example 1 This example is identical with Example 1 except that the material precipitated in the clarification of whey was separated from whey by centrifugation (4,200 g, 20 min), and the resin was Diaion HPA 75.
  • Table 1 shows data on the composition of the ⁇ and ⁇ frac ⁇ tions.
  • B bovine serum albumin
  • C ⁇ -LG
  • D ⁇ -LA
  • E orotic acid.
  • Example 3 30 cm 3 of regenerated, strong anion exchange resin Spherosil QMA LS were packed into a chromato ⁇ graphy column. 200 cm 3 of casein whey clarified as described in Example 2 were passed through the resin column at a rate of 100 cm 3 /h at pH 6.5. The column was washed with 60 cm 3 of deionized water (100 cm 3 /h) until the absorbance of the solution at the wave length of 280 nm was 0. Whey leaving the column and the wash water were combined (alpha fraction).
  • compositions of protein fractions produced as described in Examples 1 to 3 are described in Examples 1 to 3
  • the alpha fraction obtained by Diaion HPA 75 was thus of higher quality and had a higher yield than that obtained by Spherosil QMA LS.
  • Example 4 8.8 g of CaCl 2 *2H 2 0 were added to cheese whey
  • Whey (300 cm 3 ) clarified as described above was passed through a Diaion HPA 75 resin column (30 cm 3 ) at 100 cm 3 /h at pH 5.0. On leaving the column, the whey contained less than 20% of the original GMP. The ⁇ -LA concentration was unaffected by the treatment; less than 9% of the beta-lactoglobulin contained in the feed remained in the resin. GMP attached to the resin was eluted with a 4-wt.% NaCl solution, and salts were washed off the resin by deionized water. The resin was ready for re-use.
  • Example 5 Example 5
  • compositions of protein fractions produced as described in Examples 6 and 7 are Compositions of protein fractions produced as described in Examples 6 and 7
  • Phospholipoproteins were removed from cheese whey by microfiltration through a 1.4- ⁇ m membrane. 60 cm 3 of the whey so clarified were passed through 30 cm 3 of strong anion exchange resin Duolite A 101 (Rohm & Haas, France) regenerated into Cl'-form at a rate of 150 cm 3 /h at pH 5, 6, 7 and 8. At each pH, the whey was circulated through the resin for 30 min. The experiments were conducted at room temperature. After circulation, 100 cm 3 of ion-exchanged water were passed through the column, and the wash water was combined with the whey fraction (alpha-fraction). Protein attached to the column was eluted with 0.1 N HCl (beta-fraction).
  • Duolite A101 virtually bound no protein, being thus unsuitable for protein fractionation.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Dairy Products (AREA)

Abstract

The invention relates to a process for fractionating whey or whey protein solution into an alpha-lactalbumin component and a beta-lactoglobulin component, and to an alpha-lactalbumin component and a beta-lactoglobulin component so obtained. The process of the invention comprises (a) clarifying a batch of whey or whey protein solution and (b) passing whey or whey protein solution treated at stage (a) through a chromatography column packed with a strong polystyrenebased anion exchange resin, and recovering the fraction leaving the column; (c) washing the anion exchange resin column treated at stage (b) with deionized water, the obtained solution being recovered as an alpha-lactalbumin component; which is followed by (d) eluting the washed anion exchange resin column with a weak aqueous NaCl solution and recovering the eluate as a beta-lactoglobulin component.

Description

Process for fractionating whey proteins and the components so obtained.
The invention relates to a process for fractionating whey proteins. More specifically, the invention relates to a process for fractionating whey or whey protein solution chromatographically select¬ ively into an alpha-lactalbumin component and a beta- lactoglobulin component, and to an alpha-lactalbumin component and beta-lactoglobulin component so obtained. The obtained alpha-lactalbumin component is as such suitable for use in infant food formulas, and the obtained beta-lactoglobulin component in turn is as such suitable for use as a protein component in clinical nutritive preparations and various products of the food industry.
Milk whey proteins are used inter alia in infant food formulas on account of their high digestibility and excellent nutritional value. In general the pro¬ tein of infant food formulas is composed of milk casein and whey protein in a ratio of 40:60 (casein: whey protein) , which corresponds to the ratio between casein and whey protein in human milk. However, the protein composition of infant food formulas does not fully correspond to that of human milk, as the whey protein of cow's milk differs in composition from the whey protein of human milk; human milk contains no beta-lactoglobulin (β-LG), which is the main component of the whey protein of cow's milk. On the contrary, the whey protein of cow's milk, alpha-lactalbumin (α- LA), is nearly identical with the α-LA of human milk. As the protein of human milk is mainly composed of - LA (approx. 40% by weight), it would be nutritionally advantageous to use an alpha-lactalbumin fraction separated from cow's milk with the highest possible purity as the main protein component in infant food formulas.
As certain functional properties of β-LG (such as solubility within a wide pH range and good gelific- ation ability) are clearly better than those of whey protein concentrate (WPC), β-LG is regarded as well suited for use in the food industry. At present, the food industry uses WPC but is waiting for the entry into market of an economically feasible beta-lacto¬ globulin [D.M. Mulvihill, Food Research Quarterly 51 (1991) 65-73]. WPC is used e.g. in clinical nutritive preparations. In yoghurts, fresh cheeses and curd, it is used to replace casein. In curd, as much as 20% by weight of the casein can be replaced with whey pro¬ tein. Beverage industries use fatless WPC to increase the protein content of various sports drinks and soft drinks. WPC is also added to flavoured milk drinks (such as cocoa) to increase viscosity and colloidal stability. In the production of sausages, as much as 20% by weight of the protein of meat can be replaced with whey protein. WPC has also been used in the production of ice-cream, ice-lollies, meringue (only fatless WPC) and chocolate coatings [D. M. Mulvihill, Food Research Quarterly 51 (1991), 65-73].
In J. Dairy Res . , 52 (1985) 167-181, P. J. Skudder describes a process where α-LA and β-LG con¬ taining fractions can be separated from cheese or casein whey by strong anion exchange resin (Spherosil QMA, Sepracor, France). Spherosil QMA resin is composed of silica particles (diameter between 100 and 300 μm) coated with styrene vinyl triethoxysilane co- polymer to which quaternary ammonium groups are attached. This resin has a mean pore size of 1,250 A, a pore volume of 1 cm3/g and a specific surface area of 25 m2/g. This known process is based on the fact that β-LG has a higher affinity for this particular resin than other whey proteins. Accordingly, when whey is passed through a resin column regenerated into chloride form, the fraction obtained first contains only small amounts of β-LG. As the capacity of the column becomes full, β-LG also begins to leave the column. Thus a fraction containing great amounts of α- LA (alpha-fraction) is obtained by cutting off the eluate passed through the column at a suitable point. Whey protein attached to the column (beta-fraction containing mainly β-LG) can be released from the resin with a weak hydrochloric acid solution (usually 0.1 N HC1). However, Spherosil QMA resin used in the process is disadvantageous in that its particle size is small for industrial applications and it is very expensive. In U.S. Patent 5,077,067, Thibault describes a process where whey protein is fractionated e.g. by the inexpensive Duolite A101 anion exchange resin by cir¬ culating a suitable amount of whey through an ion exchange column, whereby β-LG is bound to the resin and the obtained solution is substantially free of β- LG. This is how this known process should operate in theory. However, despite a great number of experi¬ ments, it has not been proved that Duolite A101 oper¬ ates in the alleged way; contrary to what has been reported, this resin binds no β-LG. This appears from Example 8 set forth below. In addition, the Thibault process allows native whey (ash content less than 1% by weight) to be treated only within a pH range be¬ tween 4 and 6. Whey with a high salt content (ash content between 1 and 3% by weight) can be treated within a pH range between 6 and 8.
The object of this invention is to provide an industrially applicable process which avoids the above-mentioned drawbacks and which allows whey or whey protein solution to be fractionated selectively into an alpha-lactalbumin component and a beta-lacto¬ globulin component.
The invention relates to a process for frac¬ tionating whey or whey protein solution chromato- graphically selectively into an alpha-lactalbumin component and a beta-lactoglobulin component. The process is characterized by a) clarifying a batch of whey or whey protein solution and, if required, removing glycomacropeptides from it; b) passing whey or whey protein solution treated at stage a) through a chromatography column packed with a strong polystyrene-based anion exchange resin, which resin has a great pore size ranging between 1,000 and 2,000 A and a pore volume of at least 0.9 cm3/g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to a styrene-divinyl-benzene- polymer matrix, and which has a particle diameter between 300 and 600 μm, and recovering the fraction leaving the column; c) washing the anion exchange resin column treated at stage b) with deionized water, the wash water being combined with the fraction recovered at stage b), and the obtained solution being recovered as an alpha-lactalbumin component; which is followed by d) eluting the washed anion exchange resin column with a weak aqueous NaCl solution and recover¬ ing the eluate as a beta-lactoglobulin component. The process according to the invention is suitable for fractionating proteins from different types of wheys and whey protein solutions, such as cheese and casein whey, demineralized whey and whey protein concentrate. It is particularly well suited for fractionating casein whey into an alpha-lact- albumin component and a beta-lactoglobulin component.
It has now been unexpectedly found that whey or whey protein solution can be fractionated more effect¬ ively than previously by the strong anion exchange resins Diaion HPA 25 and HPA 75 (Resindion, Mitsubishi Kasei Corp., Japan), which are much cheaper than the Spherosil QMA resins. Quaternary alkyl amine (HPA 25) or alkyl alkanoamine (HPA 75) groups are attached to the styrene-divinyl-benzene-poly er matrix of these HPA resins. Due to their great pore size (1,000 to 2,000 A), pore volume (0.9 cm3/g) and specific surface area (23 to 25 m2/g), these HPA resins are suitable for separating large molecules. The price of the HPA resins is only about 1/100 of that of the Spherosil QMA resins. HPA resins are well suited for industrial applications on account of their appropriate particle size (diameter 300 too 600 μm) and mechanical strength. A further advantage of the HPA resins is that protein attached to them can be eluted by a 2 to 5 wt.% NaCl solution, whereas less safe hydrochloric acid has to be used to elute protein attached to Spherosil QMA resin in the process described by P.J. Skudder in J. Dairy Res . , 52 (1985), 167-181. The NaCl treatment is also to be preferred over HC1 from the viewpoint of preserving the nativity of the protein.
Moreover, the process according to the invention allows most of β-LG to be separated from native whey (ash content less than 1% by weight) into a fraction substantially free of other whey proteins within a pH range between 6 and 7 without pH adjustment, whereas native whey can be treated in the process described in US Patent 5,077,067 only within a pH range between 4 and 6.
The attached drawings give chromatograms obtained by Fast Protein Liquid Chromatography, FPLC, for the alpha-lactalbumin and beta-lactoglobulin fractions of whey.
Figure 1 shows FPLC chromatograms obtained for the alpha-lactalbumin and beta-lactoglobulin fractions of casein whey with HPA 75 resin according to the in¬ vention;
Figure 2 shows FPLC chromatograms obtained for the alpha-lactalbumin and beta-lactoglobulin fractions of casein whey with Spherosil QMA LS resin. At process stage a), whey or whey protein solu¬ tion is clarified by precipitating residual casein, phospholipoprotein and calcium phosphate by an in¬ crease in pH, an addition of CaCl2'2H20 and a light heat treatment, and by removing the precipitate by decantation, centrifugation or microfiltration. The clarification method does not significantly affect the protein composition of wheys.
At process stage b), whey or whey protein solu¬ tion treated at process stage a) is passed through a chromatography column packed with a strong poly¬ styrene-based anion exchange resin, which resin has a great pore size between 1,000 and 2,000 A and a pore volume of at least 0.9 cm3/g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to the styrene- divinyl-benzene-polymer matrix, and which has a par¬ ticle diameter between 300 and 600 μm, and the fraction leaving the column is recovered. Preferably, whey or whey protein solution in a corresponding amount with respect to the protein, treated at process stage a), is passed at process stage b) at a pH ranging between 6.0 and 7.0 at a flow rate of 3 to 5 column volumes per hour through a chromatography column packed with a strong polystyrene-based anion exchange resin so that 6 to 7 cm3 of whey or whey protein solution in a corresponding amount with respect to the protein are passed through the column per 1 cm3 of resin.
After clarified whey or whey protein solution has been passed at process stage b) through the column packed with the strong anion exchange chromatography resin Diaion HPA 25 or Diaion HPA 75, the β-LG con¬ centration of the whey solution passed through the column has decreased significantly and its main pro- tein component is α-LA.
At process stage c), the anion exchange resin column treated at stage b) is washed with deionized water, the wash water is combined with the fraction recovered at process stage b) and the obtained solu- tion is recovered as an alpha-lactalbumin component.
The recovered alpha-lactalbumin component can be used as such as an α-LA component particularly in infant food formulas or it can be concentrated and, if desired, dried in a manner known per se before use as an α-LA component.
At process stage d), β-LG bound to the resin column can be released from the washed anion exchange resin column by eluting with a weak aqueous NaCl solu¬ tion, preferably an aqueous 2 to 5 wt.% NaCl solution, and the eluate is recovered as a beta-lactoglobulin component. After having been rinsed with water, the resin is ready for re-use.
The recovered beta-lactoglobulin component can be used as such as a β-LG component e.g. in clinical nutritive preparations or various products of the food industry. It can also be concentrated and, if desired, dried in a manner known per se before use as a β-LG component.
Cheese whey usually contains glycomacropeptide (GMP) formed from milk casein in the production of cheese as a result of the action of a rennet enzyme. On separating the cheese mass, GMP remains in whey. It has been found that GMP deteriorates protein fraction- ation with ion exchange resins [P.J. Skudder, J. Dairy Res . , 52 (1985) 167 - 181] and that it may even cause blocking of Spherosil QMA resin. In GB Patent Appli¬ cation 2,188,526, J. Burton and P.J. Skudder describe a process utilizing Spherosil QMA for removing GMP.
It has now been unexpectedly found that GMP can be removed from whey or whey protein solution qualit¬ atively, as it can be made to attach to the strong anion exchange resin Diaion HPA 25 or HPA 75 at pH 5.0.
Glycomacropeptides possibly present in whey or whey protein solution at stage a) of the process according to the invention are thus removed by passing clarified whey or whey protein solution at pH 5.0 at a flow rate of 3 to 7 column volumes per hour through a chromatography column packed with strong polystyrene- based anion exchange resin, which resin has a great pore size between 1,000 and 2,000 A and a pore volume of at least 0.9 cm3/g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to the styrene- divinyl-benzene-polymer matrix, and which has a par¬ ticle diameter between 300 and 600 μm, so that 7 to 10 cm3 of whey or whey protein solution in a correspond¬ ing amount with respect to the protein are passed through the column per 1 cm3 of resin, and the fraction leaving the column is passed to stage b). In this way, whey or whey protein solution free of GMP is obtained.
Fractionation of whey proteins from cheese whey or cheese whey protein solution purified from GMP is significantly more efficient than from unpurified cheese whey or cheese whey protein solution, and no problems are caused by blocked columns.
In the process according to the invention, GMP can be removed considerably more economically than in the above-mentioned known process, as the expensive Spherosil QMA resin can now be replaced with the Diaion HPA 25 or HPA 75 resins, which are markedly cheaper. Moreover, HC1 can be replaced with a NaCl solution in eluting Diaion HPA 25 or HPA 75 resins. The invention also relates to an alpha-lact¬ albumin component which is useful as an α-LA component particularly in infant food formulas and which is produced by the process according to the invention.
Furthermore, the invention relates to a beta- lactoglobulin component which is useful as a β-LG protein component in the food industry in the produc¬ tion of e.g. clinical nutritive preparations and dif¬ ferent kinds of food products, such as various drinks, sausages and ice-creams, and which is produced by the process according to the invention. Example 1
The pH of casein whey (2,000 cm3) was adjusted between 7.5 and 8.5, and the whey was warmed for 30 min at 50°C, after which it was allowed to stand for 16 h at 5°C. Clear whey was separated from the pre¬ cipitated calcium phosphate, fat and lipoproteins through decantation. Clarified whey was additionally filtered through Whatman GF/A filter paper and stored at 5°C. 30 cm3 of regenerated, strong anion exchange resin Diaion HPA 25 were packed into a chromatography column. 200 cm3 of casein whey clarified as described above were passed through the resin column at a rate of 100 cm3/h at pH 6.5. The column was washed with 60 cm3 of deionized water (100 cm3/h) until the absorbance of the solution at the wave length of 280 nm was 0 (the solution no longer contained any protein) . Whey leaving the column and the wash water were combined (alpha fraction). Protein attached to the column was eluted with a 2 to 5 wt.% NaCl solution (50 cm3, 100 cm3/h) until the absorbance of the solution at the wave length of 280 nm was 0 (beta fraction). The column was rinsed with deionized water until the wash water no longer contained salt. After this the column was ready for re-use. The compositions of the fractions are shown in Table 1. Example 2
This example is identical with Example 1 except that the material precipitated in the clarification of whey was separated from whey by centrifugation (4,200 g, 20 min), and the resin was Diaion HPA 75. Table 1 shows data on the composition of the α and β frac¬ tions. Figure 1 shows the FPLC chromatograms of the α and β fractions obtained by liquid chromatography (column: Superdex 75, Pharmacia). The numerical values given in the figure indicate the retention time, A = immunoglobulins, B = bovine serum albumin (BSA), C = β-LG, D = α-LA, E = orotic acid. Example 3 30 cm3 of regenerated, strong anion exchange resin Spherosil QMA LS were packed into a chromato¬ graphy column. 200 cm3 of casein whey clarified as described in Example 2 were passed through the resin column at a rate of 100 cm3/h at pH 6.5. The column was washed with 60 cm3 of deionized water (100 cm3/h) until the absorbance of the solution at the wave length of 280 nm was 0. Whey leaving the column and the wash water were combined (alpha fraction). Protein attached to the resin column was eluted with a 0.1 N HC1 solution (50 cm3, 100 cm3/h) and rinsed with deionized water until the protein concentration of the eluate was 0 (beta fraction). The column was further rinsed until the pH of water leaving the column was more than 4.0, after which the column was ready for re-use. Table 1 shows the compositions of the fractions. Figure 2 shows the FPLC chromatograms of the α and β fractions obtained by liquid chromato¬ graphy (column: Superdex 75, Pharmacia). The numerical values given in the figure indicate the retention time, A = immunoglobulins, B = bovine serum albumin (BSA), C = β-LG, D = α-LA, E = orotic acid.
Table 1
Compositions of protein fractions produced as described in Examples 1 to 3
QMA LS HPA 25 HPA 75 α-LA β-LG α-LA β-LG α-LA β-LG
(mg) (mg) (mg) (mg) (mg) (mg)
Casein whey 98 419 101 432 122 462
(feed) α-fraction 32 20 92 116 95 44 β-fraction 66 500 7 340 28 403
Yield (%) * 100 124 98 106 101 97
*) = ((Protein in α-fraction + β-fraction)/Protein in feed) -100%
It appears from the results that Spherosil QMA
LS bound proteins most efficiently; only 5% of β-LG and 33% of α-LA was eluted in the alpha fraction, in which α-LA : β-LG = 1 : 0.63. In the beta fraction, α-LA : β-LG = 1 : 7.6. Diaion HPA resins bound pro- teins much more selectively: HPA 25 admitted 91% and HPA 75 78% of α-LA directly into the alpha fraction, whereas 79% of β-LG was bound when HPA 25 was used and 87% when HPA 75 was used (HPA 25: alpha fraction: α-LA : β-LG = 1 : 1.3; HPA 75: alpha fraction: α-LA : β-LG = 1 : 0.5). The alpha fraction obtained by Diaion HPA 75 was thus of higher quality and had a higher yield than that obtained by Spherosil QMA LS. Example 4 8.8 g of CaCl2*2H20 were added to cheese whey
(2,000 cm3), and the whey was adjusted to pH 7,3 with 1 N NaOH. The whey was warmed at 50°C for 8 min and allowed to stand at 5°C for 16 h, after which the clear whey was separated from the phospholipid pre- cipitate by decanting. Clarified whey was filtered through Whatman GF/A filter paper.
Whey (300 cm3) clarified as described above was passed through a Diaion HPA 75 resin column (30 cm3) at 100 cm3/h at pH 5.0. On leaving the column, the whey contained less than 20% of the original GMP. The α-LA concentration was unaffected by the treatment; less than 9% of the beta-lactoglobulin contained in the feed remained in the resin. GMP attached to the resin was eluted with a 4-wt.% NaCl solution, and salts were washed off the resin by deionized water. The resin was ready for re-use. Example 5
Cheese whey was clarified as described in Example 4, except that the phospholipoprotein pre- cipitate was separated from the whey by centrifug- ation. Whey so clarified (300 cm3) was passed through a Spherosil QMA LS resin column (30 cm3) at 100 cm3/h at pH 5.0. On leaving the column, the whey contained less than 20% of the original GMP. Altogether 17% of α-LA and β-LG attached to the resin. GMP attached to the resin was eluted by 0.1 N HCl solution, and the resin was washed by deionized water until the pH of the wash water leaving the column exceeded 4.0. The resin was ready for re-use.
Table 2
Protein balances of Examples 4 and 5
QMA LS HPA 75 α-LA β-LG α-LA β-LG
(mg) (mg) (mg) (mg)
Feed 188 422 228 819
Whey fraction1' 177 374 235 742
GMP fraction ND2' ND 8 21
Protein loss
(%) 3' 6 11 0 9
11 whey from which GMP has been removed
2) ND = not determined
3) Amount of alpha-lactalbumin and beta-lactoglobulin in the GMP fraction
It appears from the results that GMP can be separated relatively selectively with both resins. Protein losses were rather small.
Example 6
200 cm3 of cheese whey from which GMP had been removed as described in Example 4 were passed through Diaion HPA 75 resin (30 cm3) at a rate of 100 cm3/h at pH 6.5, after which the resin was rinsed with de¬ ionized water until the absorbance of the solution at the wave length of 280 nm was 0. Whey passed through and wash water were combined (alpha-lactalbumin fraction). Protein attached to the resin was eluted with a 5 wt.-% NaCl solution (50 cm3) (beta-lacto¬ globulin fraction). Table 3 shows the compositions of the fractions.
Example 7
295 cm3 of cheese whey from which GMP had been removed as described in Example 5 were passed through Spherosil QMA LS resin (30 cm3) at a rate of 100 cm3/h at pH 6.5, whereafter the resin was rinsed with de¬ ionized water until the solids of the solution leaving the column were 0. The whey passed through and the wash water were combined (alpha-lactalbumin fraction). Protein attached to the resin was eluted with a 0.1 N HCl solution (50 cm3) (beta-lactoglobulin fraction). The compositions of the fractions are shown in Table 3.
Table 3
Compositions of protein fractions produced as described in Examples 6 and 7
QMA LS HPA 75 α-LA β-LG α-LA β-LG
(mg) (mg) (mg) (mg)
Feed 177 374 132 366 α-fraction 117 46 97 51 β-fraction 46 314 66 396
Yield (%) 92 96 123 122
The removal of GMP significantly improved the fractionation of proteins with both resins.
Example 8
Phospholipoproteins were removed from cheese whey by microfiltration through a 1.4-μm membrane. 60 cm3 of the whey so clarified were passed through 30 cm3 of strong anion exchange resin Duolite A 101 (Rohm & Haas, France) regenerated into Cl'-form at a rate of 150 cm3/h at pH 5, 6, 7 and 8. At each pH, the whey was circulated through the resin for 30 min. The experiments were conducted at room temperature. After circulation, 100 cm3 of ion-exchanged water were passed through the column, and the wash water was combined with the whey fraction (alpha-fraction). Protein attached to the column was eluted with 0.1 N HCl (beta-fraction).
Table 4
Compositions of protein fractions produced as described in Example 8
pH 5.0 pH 6.0 pH 7.0 pH 8.0 α-LA β-LG α-LA β-LG α-LA β-LG α-LA β-LG
(mg) (mg) (mg) (mg) (mg) (mg) (mg) (mg)
Feed 47 149 46 152 52 155 45 149 α-fr. 50 147 46 151 46 148 44 149 β-fr. 0 2 0 1 6 8 1 0
It appears from the results that Duolite A101 virtually bound no protein, being thus unsuitable for protein fractionation.

Claims

Claims :
1. Process for fractionating whey or whey protein solution chromatographically selectively into an alpha-lactalbumin component and a beta-lacto¬ globulin component, c h a r a c t e r i z e d by a) clarifying a batch of whey or whey protein solution and, if required, removing glycomacropeptides from it; b) passing whey or whey protein solution treated at stage a) through a chromatography column packed with a strong polystyrene-based anion exchange resin, which resin has a great pore size ranging between 1,000 and 2,000 A and a pore volume of at least 0.9 cm3/g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to a styrene-divinyl-benzene- polymer matrix, and which has a particle diameter between 300 and 600 μm, and recovering the fraction leaving the column; c) washing the anion exchange resin column treated at stage b) with deionized water, the wash water being combined with the fraction recovered at stage b), and the obtained solution being recovered as an alpha-lactalbumin component; which is followed by d) eluting the washed anion exchange resin column with a weak aqueous NaCl solution and recover¬ ing the eluate as a beta-lactoglobulin component.
2. Process according to claim 1, c h a r a c- t e r i z e d in that glycomacropeptides possibly present in whey or whey protein solution are removed at stage a) by passing clarified whey or whey protein solution at pH 5.0 at a flow rate of 3 to 7 column volumes per hour through a chromatography column packed with strong polystyrene-based anion exchange resin, which resin has a great pore size ranging be¬ tween 1,000 and 2,000 A and a pore volume of at least 0.9 cm3/g and in which quaternary alkyl amine or alkyl alkanoamine groups, preferably alkyl alkanoamine groups, are attached to a styrene-divinyl-benzene- polymer matrix, and which has a particle diameter between 300 and 600 μm, so that 7 to 10 cm3 of whey or whey protein solution in a corresponding amount with respect to the protein are passed through the column per 1 cm3 of resin, and the fraction leaving the column is passed to stage b).
3. Process according to claim 1 or 2, c h a r¬ a c t e r i z e d by treating whey or whey protein solution which is cheese whey, casein whey, de- mineralized whey or whey protein concentrate.
4. Process according to any of claims 1 to 3, c h a r a c t e r i z e d in that whey or whey pro¬ tein solution is clarified by precipitating residual casein, phospholipoproteins and calcium phosphate possibly present in it by adjusting it to a pH value of at least 7.3 by adding 4.4 g of CaCl2*2H20 per one litre of whey and heating lightly and removing the resulting precipitate by decantation, centrifugation or microfiltration.
5. Process according to any of claims 1 to 4, c h a r a c t e r i z e d in that whey or whey pro¬ tein solution in a corresponding amount with respect to the protein, treated at stage a), is passed at stage b) at a pH ranging between 6.0 and 7.0 at a flow rate of 3 to 5 column volumes per hour through a chromatography column packed with a strong poly¬ styrene-based anion exchange resin so that 6 to 7 cm3 of whey or whey protein solution in a corresponding amount with respect to the protein are passed through the column per 1 cm3 of resin.
6. Process according to any of claims 1 to 5, c h a r a c t e r i z e d in that the anion exchange resin is eluted at stage d) with an aqueous 1 to 5 wt.% NaCl solution.
7. Process according to any of claims 1 to 6, c h a r a c t e r i z e d in that the alpha-lact¬ albumin component recovered at stage c) is concen¬ trated and possibly dried.
8. Process according to any of claims 1 to 7, c h a r a c t e r i z e d in that the beta-lacto¬ globulin component recovered at stage d) is con¬ centrated and possibly dried.
9. Alpha-lactalbumin component for use in infant food formulas, c h a r a c t e r i z e d in that it is prepared by a process according to any of claims 1 to 7.
10. Beta-lactoglobulin component for use as a protein component in the food industry, c h a r a c¬ t e r i z e d in that it is prepared by a process according to any of claims 1 to 6 and 8.
PCT/FI1995/000027 1994-01-21 1995-01-20 Process for fractionating whey proteins and the components so obtained WO1995019714A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95905668A EP0757522A1 (en) 1994-01-21 1995-01-20 Process for fractionating whey proteins and the components so obtained
AU14193/95A AU1419395A (en) 1994-01-21 1995-01-20 Process for fractionating whey proteins and the components so obtained

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI940316A FI96090C (en) 1994-01-21 1994-01-21 Method for fractionation of whey proteins
FI940316 1994-01-21

Publications (1)

Publication Number Publication Date
WO1995019714A1 true WO1995019714A1 (en) 1995-07-27

Family

ID=8539644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1995/000027 WO1995019714A1 (en) 1994-01-21 1995-01-20 Process for fractionating whey proteins and the components so obtained

Country Status (4)

Country Link
EP (1) EP0757522A1 (en)
AU (1) AU1419395A (en)
FI (1) FI96090C (en)
WO (1) WO1995019714A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096870A (en) * 1994-01-05 2000-08-01 Sepragen Corporation Sequential separation of whey
WO2001041580A1 (en) * 1999-12-08 2001-06-14 Fonterra Co-Operative Group Limited Method of obtaining glyco-macro-peptide deplete product from whey
EP1234507A1 (en) * 2001-02-26 2002-08-28 Wageningen Centre for Food Sciences Process for isolating beta-lactoglobulin from milk or milk fractions
WO2004067557A1 (en) * 2003-01-31 2004-08-12 Henkel Kommanditgesellschaft Auf Aktien Methods for refining concentrated enzyme solutions
US7018665B2 (en) 1999-12-08 2006-03-28 Massey University Process for separation of whey proteins using a novel anion exchanger
FR2889067A1 (en) * 2005-07-29 2007-02-02 Cie Laitiere Europ Soc En Comm Using protein fraction from whey for control of body weight, e.g. to promote slimming, comprises beta-lactoglobulin and alpha-lactalbumin at specified ratio
US7651716B2 (en) 2001-12-21 2010-01-26 Wyeth Llc Methods for reducing adverse effects of feeding formula to infants
WO2010037736A1 (en) * 2008-09-30 2010-04-08 Upfront Chromatography A/S A METHOD FOR PROVIDING A β-LACTOGLOBULIN PRODUCT AND AN α-ENRICHED WHEY PROTEIN ISOLATE
CN102590413A (en) * 2012-01-18 2012-07-18 浙江省疾病预防控制中心 Quantitative detection method for bovine alpha-lactalbumin
US9055752B2 (en) 2008-11-06 2015-06-16 Intercontinental Great Brands Llc Shelf-stable concentrated dairy liquids and methods of forming thereof
WO2016023553A1 (en) * 2014-08-15 2016-02-18 Upfront Chromatography A/S Method for separating alpha-lactalbumin and beta-lactoglobulin
WO2016055064A3 (en) * 2014-10-06 2016-06-09 Upfront Chromatography A/S Isolation of soluble proteins from aggregated casein-containing mixtures
US11490629B2 (en) 2010-09-08 2022-11-08 Koninklijke Douwe Egberts B.V. High solids concentrated dairy liquids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF DAIRY SCIENCE, Volume 73, No. 9, 1990, SHIGERU YOSHIDA, "Isolation of beta-Lactoglobulin and alpha-Lactalbumin by Gel Filtration Using Sephacryl S-200 and Purification by Diethylaminoethyl Ion-Exchange Chromatography", page 2292 - page 2298. *
MILCHWISSENSCHAFT, Volume 42, No. 11, 1987, A.R. HILL et al., "Quantification and Characterization of Whey Protein Fractions Separated by Anion Exchange Chromatography", page 693 - page 696. *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096870A (en) * 1994-01-05 2000-08-01 Sepragen Corporation Sequential separation of whey
WO2001041580A1 (en) * 1999-12-08 2001-06-14 Fonterra Co-Operative Group Limited Method of obtaining glyco-macro-peptide deplete product from whey
US7018665B2 (en) 1999-12-08 2006-03-28 Massey University Process for separation of whey proteins using a novel anion exchanger
EP1234507A1 (en) * 2001-02-26 2002-08-28 Wageningen Centre for Food Sciences Process for isolating beta-lactoglobulin from milk or milk fractions
US7651716B2 (en) 2001-12-21 2010-01-26 Wyeth Llc Methods for reducing adverse effects of feeding formula to infants
WO2004067557A1 (en) * 2003-01-31 2004-08-12 Henkel Kommanditgesellschaft Auf Aktien Methods for refining concentrated enzyme solutions
FR2889067A1 (en) * 2005-07-29 2007-02-02 Cie Laitiere Europ Soc En Comm Using protein fraction from whey for control of body weight, e.g. to promote slimming, comprises beta-lactoglobulin and alpha-lactalbumin at specified ratio
EP2801260A1 (en) * 2008-09-30 2014-11-12 Upfront Chromatography A/S An alpha-enriched whey protein isolate
WO2010037736A1 (en) * 2008-09-30 2010-04-08 Upfront Chromatography A/S A METHOD FOR PROVIDING A β-LACTOGLOBULIN PRODUCT AND AN α-ENRICHED WHEY PROTEIN ISOLATE
US9035031B2 (en) 2008-09-30 2015-05-19 Upfront Chromatography A/S Method for providing a β-lactoglobulin product and an α-enriched whey protein isolate
US9055752B2 (en) 2008-11-06 2015-06-16 Intercontinental Great Brands Llc Shelf-stable concentrated dairy liquids and methods of forming thereof
US11490629B2 (en) 2010-09-08 2022-11-08 Koninklijke Douwe Egberts B.V. High solids concentrated dairy liquids
CN102590413B (en) * 2012-01-18 2013-12-25 浙江省疾病预防控制中心 Quantitative detection method for bovine alpha-lactalbumin
CN102590413A (en) * 2012-01-18 2012-07-18 浙江省疾病预防控制中心 Quantitative detection method for bovine alpha-lactalbumin
WO2016023553A1 (en) * 2014-08-15 2016-02-18 Upfront Chromatography A/S Method for separating alpha-lactalbumin and beta-lactoglobulin
CN106793797A (en) * 2014-08-15 2017-05-31 预层析股份有限公司 The method for separating alpha-lactalbumin and beta lactoglobulin
WO2016055064A3 (en) * 2014-10-06 2016-06-09 Upfront Chromatography A/S Isolation of soluble proteins from aggregated casein-containing mixtures

Also Published As

Publication number Publication date
EP0757522A1 (en) 1997-02-12
FI96090B (en) 1996-01-31
AU1419395A (en) 1995-08-08
FI940316A (en) 1995-07-22
FI96090C (en) 1996-05-10
FI940316A0 (en) 1994-01-21

Similar Documents

Publication Publication Date Title
Etzel Manufacture and use of dairy protein fractions
WO1995019714A1 (en) Process for fractionating whey proteins and the components so obtained
AU661090B2 (en) Process for the production of biologically active substances from milk and related raw materials
EP0620709B1 (en) Process for isolating lactoferrin and lactoperoxidase from milk and milk products
EP0390821A1 (en) Process for extracting pure fractions of lactoperoxidase and lactoferrin from milk serum.
AU664934B2 (en) Process for the recovery of alpha-lactalbumin and beta-lactoglobulin from a whey protein product
De Wit et al. Evaluation of functional properties of whey protein
NZ500848A (en) Method for purifying GMP from a lactic raw material
US5194591A (en) Isolation of an immunoglobulin rich fracton from whey
US4834994A (en) Method for removing β-lactoglobulin from bovine milk whey
IE861576L (en) Separating alpha-lactalbumin from whey proteins dna segment conferring high frequency transduction of¹recombinant dna vectors
Pearce Whey protein recovery and whey protein fractionation
US6555659B1 (en) Process for isolating glycomacropeptide from dairy products with a phenylalanine impurity of 0.5% w/w
CA2242931A1 (en) Production of an immunoglobulin enriched fraction from whey protein solutions
WO2002028194A1 (en) Process for recovering proteins from whey protein containing feedstocks
JP2001516599A (en) Sequential separation of whey proteins and formulations thereof
NZ237077A (en) Non-protein nitrogen compound from whey for a formulated milk composition
NZ243727A (en) Isolation of charged particles from fluids by ion exchange where the ion exchange medium is disposed on a porous membrane
AU777698B2 (en) Process for separation of whey proteins using a novel anion exchanger
JP3161846B2 (en) Separation of sialic acid-binding peptides in milk whey
EP0518448B1 (en) A method for isolating proteins from milk and a method for processing milk
AU1313401A (en) Method of obtaining immunoglobulins from colostrum and dairy sources
CN110267968B (en) Purification method of whey protein
IE920012A1 (en) Process for the separation of whey proteins and products¹obtained
IE60982B1 (en) Method for removing beta-lactoglobulin from bovine milk whey

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995905668

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995905668

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995905668

Country of ref document: EP